Sleep Disorders in Spinocerebellar Ataxia Type 2 Patients
Authors:
- Ursula VossUVUrsula Voss
- Roberto Rodríguez-LabradaRRRoberto Rodríguez-Labrada
- Georg AuburgerGAGeorg Auburger
- Nalia Canales OchoaNONalia Canales Ochoa
- Gilberto Sánchez CruzGCGilberto Sánchez Cruz
- Raúl Aguilera RodríguezRRRaúl Aguilera Rodríguez
- Jacqueline Medrano MonteroJMJacqueline Medrano Montero
- Jose M. Laffita MesaJMJose M. Laffita Mesa
- Inka TuinITInka Tuin
- 15 April 2011
- journal article
- Published by S. Karger AG in Neurodegenerative Diseases
- Vol. 8 (6) , 447-454
Abstract
Background: Sleep disturbances are common features in spinocerebellar ataxias (SCAs). Nevertheless, sleep data on SCA2 come from scarce studies including few patients, limiting the evaluation of the prevalence and determinants of sleep disorders. Objective: To assess the frequency and possible determinants of sleep disorders in the large and homogeneous SCA2 Cuban population. Methods: Thirty-two SCA2 patients and their age- and sex-matched controls were studied by video-polysomnography and sleep interviews. Results: The most striking video-polysomnography features were rapid eye movement (REM) sleep pathology and periodic leg movements (PLMs). REM sleep abnormalities included a consistent reduction of the REM sleep percentage and REM density as well as an increase in REM sleep without atonia (RWA). REM sleep and REM density decreases were closely related to the increase in ataxia scores, whereas the RWA percentage was influenced by the cytosine-adenine-guanine (CAG) repeats. PLMs were observed in 37.5% of cases. The PLM index showed a significant association with the ataxia score and disease duration but not with CAG repeats. Conclusions: REM sleep pathology and PLMs are closely related to SCA2 severity, suggesting their usefulness as disease progression markers. The RWA percentage is influenced by the CAG repeats and might thus be a sensitive parameter for reflecting polyglutamine toxicity. Finally, as PLMs are sensible to drug treatment, they represents a new therapeutic target for the symptomatic treatment of SCA2.Keywords
This publication has 35 references indexed in Scilit:
- Molecular epidemiology of spinocerebellar ataxias in Cuba: Insights into SCA2 founder effect in HolguinNeuroscience Letters, 2009
- Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategiesThe Cerebellum, 2008
- Spinocerebellar ataxia 2 (SCA2)The Cerebellum, 2008
- Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2)Neurology, 2006
- Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: Striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomographyMovement Disorders, 2006
- Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2Movement Disorders, 2006
- Scale for the assessment and rating of ataxiaNeurology, 2006
- Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3Journal of Neurology, 2001
- Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2Nature Genetics, 1996
- Anticipation in spinocerebellar ataxia type 2Nature Genetics, 1993